Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.
This EAP has been established to provide access to daraxonrasib to patients with previously treated metastatic pancreatic adenocarcinoma during the period before potential commercial availability. Patients may be eligible if they have progressed on, are intolerant of, or are no longer expected to benefit from available standard therapies, and if they are not able to enroll in a clinical trial of daraxonrasib due to ineligibility or lack of access. This EAP is intended to address an unmet medical need and is not designed to support clinical development objectives.
Daraxonrasib is an investigational, orally administered, RAS(ON) inhibitor administered as monotherapy. Daraxonrasib will be supplied by the Sponsor free of charge during the duration of treatment under this program.
Inclusion Criteria:
Exclusion Criteria:
medinfo@revmed.com1-844-2-REVMED
Fresno, California 93720, United States
Boca Raton, Florida 33487, United States
Orlando, Florida 33308, United States
Detroit, Michigan 48201, United States
Morristown, New Jersey 07960, United States
Oklahoma City, Oklahoma 73104, United States
Pittsburgh, Pennsylvania 15224, United States
Greer, South Carolina 29651, United States
Lubbock, Texas 79410, United States
Fredericksburg, Virginia 22408, United States